



PREFERENTIALLY RECOMMENDED FOR 65+ OVER STANDARD-DOSE FLU VACCINES¹

ACIP preferentially recommends adjuvanted and higher dose vaccines over standard-dose influenza vaccines for adults 65 years and older.¹

An ACIP systematic review examined **RCT and RWE data** to assess the relative benefits and harms of any adjuvanted or higher dose vaccines compared with standard-dose influenza vaccines and compared with one another in adults 65+. Evidence did not indicate superiority of any higher dose or adjuvanted vaccine over the other.¹

ACIP Recommendation for 65+¹

Adults aged ≥ 65 years preferentially receive any one of the following **adjuvanted** or **higher dose** influenza vaccines*:

- **quadrivalent adjuvanted inactivated influenza vaccine (aIIV4)**
- **quadrivalent high-dose inactivated influenza vaccine (HD-IIV4)**
- **quadrivalent recombinant influenza vaccine (RIV4)**

If none of these three vaccines is available at an opportunity for vaccine administration, then any other age-appropriate influenza vaccine should be used.

For the full
ACIP seasonal
influenza vaccine
recommendations
(*Morbidity and
Mortality Weekly
Report—MMWR*),
[click here.](#)

Give your patients 65+ the Adjuvant Advantage^{†1}

FLUAD[®] QUADRIVALENT (Influenza Vaccine, Adjuvanted) is the first and only adjuvanted flu vaccine designed to address a weakened immune system and strain mismatch by boosting the immune response of adults 65+ more than antigen alone.²⁻⁵ [Visit flu360.com](http://flu360.com) for more details on **FLUAD QUADRIVALENT**.

*Adjuvanted or higher dose influenza vaccines include FLUAD[®] QUADRIVALENT, FLUZONE[®] HIGH-DOSE QUADRIVALENT, and FLUBLOK[®] QUADRIVALENT.

[†]Preferentially recommended by ACIP for adults 65+ over non-adjuvanted, standard-dose influenza vaccines.

ACIP=Advisory Committee on Immunization Practices; RCT=randomized controlled trial; RWE=real-world evidence

FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted)

INDICATION and IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

FLUAD QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUAD QUADRIVALENT is approved for use in persons 65 years of age and older.

This indication is approved under accelerated approval based on the immune response elicited by FLUAD QUADRIVALENT. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

WARNINGS AND PRECAUTIONS

If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD QUADRIVALENT. Ensure procedures are in place to avoid injury from falling associated with syncope.

REFERENCES: 1. Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices — United States, 2023–24 influenza season. *MMWR Recomm Rep.* 2023;72(2):1-25. 2. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. *Vaccine.* 2012;30(29):4341-4348. 3. O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. The history of MF59® adjuvant: a phoenix that arose from the ashes. *Expert Rev Vaccines.* 2013;12(1):13-30. 4. Banzhoff A, Pellegrini M, Del Giudice G, Fraganpane E, Groth N, Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. *Influenza Other Respir Viruses.* 2008;2(6):243-249. 5. FLUAD QUADRIVALENT. Package insert. Seqirus Inc.

For US Healthcare Professional Use Only

flu360 and FLUAD QUADRIVALENT are registered trademarks of Seqirus UK Limited or its affiliates. All other trademarks are property of their respective owners. Seqirus USA Inc., 25 Deforest Avenue, Summit, NJ 07901, USA ©2023 Seqirus USA Inc. November 2023 USA-aQIV-23-0043

The immune response to FLUAD QUADRIVALENT in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

Vaccination with FLUAD QUADRIVALENT may not protect all vaccine recipients against influenza disease.

ADVERSE REACTIONS

The most common ($\geq 10\%$) local and systemic reactions in elderly subjects 65 years of age and older were injection site pain (16.3%), headache (10.8%) and fatigue (10.5%). Other adverse events may occur.

To report SUSPECTED ADVERSE REACTIONS, contact CSL Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 and www.vaers.hhs.gov.

Before administration, please see the full [Prescribing Information](#) for FLUAD QUADRIVALENT.

FLUAD® QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.

CSL Seqirus